The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs

Cancer Research

Volumn 63, Issue 2, 2003, Pages 505-512

  Desmond, Julian C ^a   Mountford, Joanne C ^a   Drayson, Mark T ^a   Walker, Elizabeth A ^a   Hewison, Martin ^a   Ride, Jonathan P ^a   Luong, Quang T ^a   Hayden, Rachel E ^a   Vanin, Elio F ^b   Bunce, Christopher M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 KETOREDUCTASE; 2 CHLORO 5 NITROBENZANILIDE; ALDO KETO REDUCTASE 1C3; ALDO KETO REDUCTASE 1C3 INHIBITOR; CALCITRIOL; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROSTAGLANDIN D2; PROSTAGLANDIN F2; PROSTAGLANDIN J2; PROSTAGLANDIN SYNTHASE; RETINOIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN HL 60; DESENSITIZATION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

3-ALPHA-HYDROXYSTEROID DEHYDROGENASE (B-SPECIFIC); 3-HYDROXYSTEROID DEHYDROGENASES; ANDROSTANE-3,17-DIOL; ANILIDES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CALCITRIOL; CELL DIFFERENTIATION; DIHYDROTESTOSTERONE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION; HL-60 CELLS; HUMANS; PROSTAGLANDIN D2; TRANSGENES; TRETINOIN;

EID: 0037439967     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Xu, X. C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs, 13: 127-137, 2002.
2. Stack, E., and DuBois, R. N. Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol. Clin. North Am., 30: 1001-1010, 2001.
3. Gupta, R. A., and Dubois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 1: 11-21, 2001.
4. Grösch, S., Tegeder, I., Niederberger, E., Bräutigam, L., and Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J., 15: 2742-2744, 2001.
5. Zhang, X., Morham, S. G., Langenbach, R., and Young, D. A. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med., 190: 451-459, 1999.
6. Wechter, W. J. Kantoci, D., Murray, E. D., Jr., Quiggle, D. D., Leipold, D. D., Gibson, K. M., and McCracken, J. D. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res., 57: 4316-4324, 1997.
7. Wechter, W. J. Leipold, D. D., Murray, E. D., Jr., Quiggle, D., McCracken, J. D., Barrios, R. S., and Greenberg, N. M. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res., 60: 2203-2208, 2000.
8. Tegeder, I., Pfeilschifter, J., and Geisslinger, G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J., 15: 2057-2072, 2001.
9. Lin, H. K., Jez, J. M., Schlegel, B. P., Peehl, D. M., Pachter, J. A., and Penning, T. M. Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution. Mol. Endocrinol., 11: 1971-1984, 1997.
10. Pawlowski, J., Huizinga, M., and Penning, T. M. Isolation and partial characterization of a full-length cDNA clone for 3α-hydroxysteroid dehydrogenase: a potential target enzyme for nonsteroidal anti-inflammatory drugs. Agents Actions, 34: 289-293, 1991.
11. Matsuura, K., Shiraishi, H., Hara, A., Sato, K., Deyashiki, Y., Ninomiya, M., and Sakai, S. Identification of a principal mRNA species for human 3α-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J. Biochem. (Tokyo), 124: 940-946, 1998.
12. Penning, T. M., Burczynski, M. E., Jez, J. M., Lin, H. K., Ma, H., Moore, M., Ratnam, K., and Palackal, N. Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Mol. Cell. Endocrinol., 171: 137-149, 2001.
13. Penning, T. M., Burczynski, M. E., Jez, J. M., Hung, C. F., Lin, H. K., Ma, H., Moore, M., Palackal, N., and Ratnam, K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J., 351: 67-77, 2000.
14. Mills, K. I., Gilkes, A. F., Sweeney, M., Choudhry, M. A., Woodgate, L. J., Bunce, C. M., Brown G., and Burnett, A. K. Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Lett. 440: 158-162, 1998.
15. Nagase, T., Miyajima, N., Tanaka, A., Sazuka, T. Seki, N., Sato, S., Tabata, S., Ishikawa, K., Kawarabayasi, Y., Kotani, H., and Nomura, N. Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res., 2: 37-43, 1995.
16. Sokoloski, J. A., and Sartorelli, A. C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3. Leuk. Res., 22: 153-161, 1998.
17. Bunce, C. M., Mountford, J. C., French, P. J., Mole, D. J., Durham, J., Michell, R. H., and Brown, G. Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochem. Biophys. Acta., 1311: 189-198, 1996.
18. Straus, D. S., and Glass, C. K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev., 21: 185-210, 2001.
19. Persons, D. A., Mehaffey, M. G., Kaleko, M., Nienhuis, A. W., and Vanin, E. F. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Mol. Dis., 24: 167-182, 1998.
20. Persons, D. A., Allay, J. A., Allay, E. R., Smeyne, R. J., Ashmun, R. A., Sorrentino, B. P., and Nienhuis, A. W. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood. 90: 1777-1786, 1997.
21. Yang, Y., Vanin, E. F., Whitt, M. A., Fornerod, M., Zwart, R., Schneiderman, R. D., Grosveld, G., and Nienhuis, A. W. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum. Gene. Ther., 6; 1203-1213, 1995.
22. Bendixen, A. C., Shevde, N. K., Dienger, K. M., Willson, T. M., Funk, C. D., and Pike, J. W. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1. Proc. Natl. Acad. Sci. USA, 98: 2443-2448, 2001.
23. Jez, J. M., Bennett, M. J., Schlegel, B. P., Lewis, M., and Penning, T. M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 326: 625-636, 1997.
24. Honda, A., Raz, A., and Needleman, P. Induction of cyclo-oxygenase synthesis in human promyelocytic leukaemia (HL-60) cells during monocytic or granulocytic differentiation. Biochem. J., 272: 259-262, 1990.
25. Jang, M., and Pezzuto, J. M. Cancer chemopreventative activity of resveratrol. Drugs Exp. Clin. Res., 25; 65-77, 1999.
26. Koll, S., Goppelt-Struebe, M., Hauser, I, and Goerig, M. Monocytic-endothelial cell interaction: regulation of prostanoid synthesis in human co-culture. J. Leukoc. Biol., 61; 679-688, 1997.
27. Danel, L., Menouni, M., Cohen, J. H., Magaud, J. P., Lenoir, G., Revillard, J. P., and Saez, S. Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines. Leuk Res., 9; 1373-1378, 1985.
28. Tsao, C. J., Ozawa, K., Hosoi, T., Urabe, A., and Takaku, F. In vitro effects of antineoplastic prostaglandins on human leukemic cell growth and normal myelopoiesis. Leuk. Res., 10: 527-532, 1986.
29. Asou, H., Verbeek, W., Williamson, E., Elstner, E., Kubota, T., Kamada, N., and Koeffler, H. P. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor γ, and retinoids. Int. J. Oncol., 15: 1027-1031, 1999.
30. Ujihara, M., Urade, Y., Eguchi, N., Hayashi, H., Ikai, K., and Hayaishi, O. Prostaglandin D2 formation and characterization of its synthetases in various tissues of adult rats. Arch. Biochem. Biophys., 260: 521-531, 1988.
31. Bogaards, J. J., Venekamp, J. C., and van Bladeren, P. J. Stereoselective conjugation of prostaglandin A2 and prostaglandin J2 with glutathione, catalyzed by the human glutathione S-transferases A1-1, A2-2, M1a-1a, and P1-1. Chem. Res. Toxicol., 10: 310-317, 1997.
32. Ellis, C. K., Smigel, M. D., Oates, J. A., Oelz, O., and Sweetman, B. J. Metabolism of prostaglandin D2 in the monkey. J. Biol. Chem., 254: 4152-4163, 1979.
33. Person, E. C., Waite, L. L., Taylor, R. N., and Scanlan, T. S. Albumin regulates induction of peroxisome proliferator-activated receptor-γ (PPARγ) by 15-deoxyδ(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARγ function in vivo. Endocrinology, 142: 551-556, 2001.
34. Chen, Y., Morrow, J. D., and Roberts, L. J., II. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J. Biol. Chem., 274: 10863-10868, 1999.
35. Hirata, Y., Hayashi, H., Ito, S., Kikawa, Y., Ishibashi, M., Sudo, M., Miyazaki, H., Fukushima, M., Narumiya, S., and Hayaishi, O. Occurrence of 9-deoxy-δ9,δ12-13,14-dihydroprostaglandin D2 in human urine. J. Biol. Chem., 263: 16619-16625, 1988.
36. Reginato, M. J., Krakow, S. L., Bailey, S. T., and Lazar, M. A. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferatoractivated receptor γ. J. Biol. Chem., 273: 1855-1858, 1998.
37. Fontagne, J., Adolphe, M., Semichon, M., Zizine, L., and Lechat, P. Effect of in vitro treatment with indomethacin on mouse granulocyte-macrophage colony forming cells in culture (CFUC). Possible role of prostaglandins. Exp. Hematol., 8; 1157-1164, 1980.
38. Pelus, L. M. Blockade of prostaglandin biosynthesis in intact mice dramatically augments the expansion of committed myeloid progenitor cells (colony-forming units-granulocyte, macrophage) after acute administration of recombinant human IL-1α. J. Immunol., 143; 4171-4179, 1989.
39. O'Reilly, M., and Gamelli, R., L. Indomethacin augments granulocyte-macrophage colony stimulating factor-induced hematopoiesis following 5-FU treatment. Exp. Hematol., 18; 974-978, 1990.
40. Gamelli, R., L., He, L., K., and Liu, H. Marrow granulocyte-macrophage progenitor cell response to burn injury as modified by endotoxin and indomethacin. J. Trauma, 37; 339-346, 1994.
41. Sasaki, H., and Fukushima, M. Prostaglandins in the treatment of cancer. Anticancer Drugs, 5: 131-138, 1994.
42. Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S. Miyoshi, I., and Koeffler, H. P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344-3352, 1998.
43. 12,14-prostaglandin J2. Cell Growth Differ., 11: 49-61, 2000.
44. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med., 4: 1046-1052, 1998.
45. Desreumaux, P. Dubuquoy, L., Nutten, S., Peuchmaur, M., Englaro, W., Schoonjans, K., Derijard, B., Desvergne, B., Wahli, W., Chambon, P., Leibowitz, M. D., Colombel, J. F., and Auwerx, J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J. Exp. Med., 193: 827-838, 2001.
46. Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., and Hosokawa, M. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res., 61: 2424-2428, 2001.
47. Hisatake, J. I., Ikezoe, T., Carey, M., Holden, S., Tomoyasu, S., and Koeffler, H. P. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Res., 60: 5494-5498, 2000.
48. Giovannucci, E., Rimm, E. B., Liu, Y., Stampfer, M. J., and Willett, W. C. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. (Bethesda), 94: 391-398, 2002.
49. Kennedy, A. R. The evidence for soybean products as cancer preventive agents. J. Nutr., 125: 733S-743S, 1995.
50. Messina, M. J., Persky, V., Setchell, K. D., and Barnes, S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer. 21: 113-131, 1994.
51. Krazeisen, A., Breitling, R., Moller, G., and Adamski, J. Phytoestrogens inhibit human 17β-hydroxysteroid dehydrogenase type 5. Mol. Cell. Endocrinol., 171: 151-162, 2001.